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Background: Arthropod-borne viral encephalitis of diverse origins shows similar clinical symptoms, histopathology
and magnetic resonance imaging, indicating that the patho mechanisms may be similar. There is no specific therapy
to date. However, vaccination remains the best prophylaxis against a selected few. Regardless of these shortcomings,
there are an increasing number of case reports that successfully treat arboviral encephalitis with high doses of
intravenous immunoglobulins.
Discussion: To our knowledge, high dose intravenous immunoglobulin has not been tested systematically for treating
severe cases of tick-borne encephalitis. Antibody-dependent enhancement has been suspected, but not proven,
in several juvenile cases of tick-borne encephalitis. Although antibody-dependent enhancement during secondary
infection with dengue virus has been documented, no adverse effects were noticed in a controlled study of high
dose intravenous immunoglobulin therapy for dengue-associated thrombocytopenia. The inflammation-dampening
therapeutic effects of generic high dose intravenous immunoglobulins may override the antibody-dependent
enhancement effects that are potentially induced by cross-reactive antibodies or by virus-specific antibodies at
sub-neutralizing levels.
Summary: Analogous to the increasing number of case reports on the successful treatment of other arboviral
encephalitides with high dose intravenous immunoglobulins, we postulate whether it may be possible to also treat
severe cases of tick-borne encephalitis with high dose intravenous immunoglobulins as early in the course of the
disease as possible.
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Tick-borne encephalitis (TBE): epidemiology, radiologic
findings and pathology
Together with other prominent human pathogenic ar-
thropod-borne (arbo) viruses, such as yellow fever virus
(YFV), dengue virus (DENV), Japanese encephalitis virus
(JEV), West-Nile virus (WNV) and other less known rel-
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reproduction in any medium, provided the orto the Flaviviridae family (for review see [1]). Flaviviruses
are enveloped viruses with a single-stranded RNA in
positive-strand orientation. Three TBEV subtypes, namely
the European, the Siberian and the Far-Eastern subtype,
are endemic to different geographical areas in Europe and
Asia. The Western TBEV subtype is mainly transmitted by
the tick species Ixodes (I.) ricinus, while the Eastern
subtypes are mainly transmitted by the tick species I.
persulcatus from rodents and other small mammals. Vac-
cination is highly effective in preventing TBE disease and
is recommended for residents exposed to TBEV within
the endemic areas [2]. Firstly, after an incubation period oftd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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disease involves a flu-like illness of four (1 to 8) days,
allowing the virus to become viremic. Secondly, after a lag
period of one week (1 to 33 days), an invasion occurs of the
entire reticulo-endothelial system and the central nervous
system (CNS). The virus is neurotropic and causes me-
ningitis, meningoencephalitis, meningoencephalomyelitis or
meningoencephalomyeloradiculitis, and may result in long-
lasting or permanent neurological damage, known as post-
encephalitic syndrome. In recent years, between 2,000 and
4,000 clinical cases were reported annually for Europe ex-
cluding regions of Russia and Asia [1,3]. Since mild flu-like
disease occurs more frequently (an estimated 70 to 80% of
cases) than neurological disease, the real case numbers are
estimated to be much higher than the reported ones [3].
Full recovery takes place in slightly more than half of the
reported clinical cases, while slightly less than half of the
patients are afflicted with residual sequelae. The disease is
fatal in less than 1% of European subtype TBE cases, but
the lethality of the two Eastern TBEV subtypes is much
higher [1]. In elder patients, severe disease courses are more
frequent than in children, but severe courses also occur in
children (for review see [4,5]). It has not been systematically
resolved, whether antibody-dependent enhancement (ADE)
may have taken place in some childhood TBE cases after
post-exposure prophylaxis [6-8], as it has been described
for secondary DENV infection. While enhancement was
observed in cell culture [9], it has not been found in TBE-
infected mice, after passive pre- or post-exposure prophy-
laxis had been given [10].
Widespread lesions in the CNS may involve gray matter
and leptomeninges of the brain stem, medulla oblongata,
nuclei, cerebellum and spinal cord (for review see [4,5]). A
prominent perivascular infiltration by activated inflamma-
tory cells such as macrophages and leukocytes is observed.
Furthermore, neuronal degeneration, necrosis and neuro-
nophagia occur. Elevated intrathecal neopterin that is se-
creted by stimulated macrophages indicates a high degree
of macrophage and T-cell activation [11]. Magnetic reson-
ance imaging (MRI) is reported as normal in the majority
of cases [12]. However, enhanced signals in T2-weighted
MRI scans have been regularly observed in the acute
phase of severe TBE [13] and sometimes for extended time
periods in protracted disease courses [6,8]. MRI studies
demonstrated CNS damage mainly in the thalamus, cere-
bellum, nucleus caudatus and the brain stem [14].
The mechanisms by which TBEV causes encephalitis
are not completely understood, but a composite of direct
cytolytic viral damage and of considerable immune path-
ology is likely. Mouse models of TBE disease demon-
strated that immune pathology contributed significantly
to the neurological damage in TBE [15]. On the one
hand, normal mice succumbed to the CNS inflammation
caused by TBEV infection, while CD8-knockout mice, ormice with a severe combined immune deficiency (SCID),
exhibited prolonged survival. On the other hand, the
adoptive transfer of CD8+ T-cells to infected SCID mice
significantly shortened their survival, while the transfer of
CD4+ T-cells prolonged their survival. The viral load was
the same in normal mouse strains and in CD8-knockout
mice, while it was higher in SCID mice. The histological
brain lesions were more moderate in immune suppressed
mouse strains than in immunocompetent mice. The in-
flammatory infiltrates around meningeal vessels consisted
mainly of CD8+ T-cells, and contained also histiocytes,
but little CD4+ T-cells. These experiments proved a key
role for the CD8+ T-cells in the pathology of TBE, and
that TBE is essentially an immunopathological disease
[15]. Moreover, experimental immune suppressive therapy
with Cyclophosphamide led to an increased survival time
of TBEV-infected mice [16]. The CNS pathology induced
by other flaviviruses, such as WNV and Murray Valley
encephalitis virus, was also more caused by the immune
system than by cytolytic virus replication. Like in TBE,
CD8+ T-cells were the main culprits for the immune dam-
age caused by WNV, while CD4+ T-cells prolonged the
survival of WNV infected mice [15,17]. Contrary to TBE,
where the viral load was not correlated with the presence
or absence of CD8+ T-cells, WNV load was lower in im-
munocompetent mice. Both in TBEV and WNV encephal-
itis, CD8+ T-cells were required for the eventual clearance
of WNV from the organism and for mouse survival
[15,18]. This shows that part of the neuronal damage is
also directly due to virus infection [15,19]. Thus, the
mouse experiments indicate that an immunomodulatory
treatment that dampens the inflammatory immune re-
sponse, while not disabling it, may help curbing flaviviral
CNS pathology. A case in point was the rapid recovery of
TBE patients from their clinical symptoms that were
treated with the immunomodulatory antibiotic tetracyc-
line that reduced an inflammatory response [20].
There is no specific treatment currently available for
TBEV disease. Since immune modulation by tetracycline
was helpful, immunomodulatory therapy may be the way
to go [20]. Ideal therapy will (i) enhance protective im-
mune reactions, (ii) normalize immune regulation, and (iii)
suppress the damaging mechanisms by the immune re-
sponse. A well-proven option of immune modulation is to
administrate a generic high dose (1 to 2 grams per kilo-
gram body weight) of intravenous immunoglobulins (IVIG)
over a time course of 2 to 5 days. This is a similar treat-
ment given for several acute hyper inflammatory auto-
immune conditions, e.g. Kawasaki vasculitis, Guillain-Barré
syndrome, myasthenia gravis, immune thrombocytopenia,
macrophage activation syndromes, acute encephalitis, or
may also be given as an adjunctive therapy for sepsis
[21-24]. The best known effects of high dose IVIG are (i)
blocking Fc receptors of macrophages, thereby occluding
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thelial system, (ii) blocking the complement activation by
abrogating the ability of aggregated antibodies to lead to
complement activation, and through scavenging of com-
plement components, (iii) specifically neutralizing patho-
gens by anti-pathogen antibodies present in the mixture.
The mechanisms of reducing inflammatory cytokines, sup-
pressing T-cell responses and dampening inflammatory re-
actions in general are not entirely clear yet [21-24].
Discussion
Case report collection
The neuropathological and neuroradiological findings of
various arboviral encephalitides are similar in nature and
therefore non-specific [13,25]. Therefore, it is interesting
to note a series of case reports on successful interven-
tion with high dose IVIG in severe cases of viral enceph-
alitis of arboviral origin, other than flaviviruses and of
flaviviral origin other than TBEV. However, to our
knowledge, the early intervention with high dose IVIG
in severe TBE cases has not been reported so far. The
following case reports are grouped together with respect
to the viral cause. An overview of the case reports is
given in Table 1.
Tick-borne encephalitis virus
A 54 year old man had a severe and complicated TBE
infection, after a complete vaccination against TBE with
two boosters. He received the last booster 39 months be-
fore his disease. After two weeks the patient developed
sinus tachycardia, hypertonia and gastrointestinal tract
dysfunction. These symptoms and a fixed heart rate were
taken as signs of autonomic failure. Late after diseaseTable 1 Listing of case reports of viral encephalitis
patients who were treated with high dose intravenous
immunoglobulin (IVIG)
Arboviruses Encephalitis Haemorrhagic fever Refs.
TBEV (flavivirus) 1 [26]
JEV (flavivirus) 2 [28-30]
DENV (flavivirus) 15 [31]
WNV (flavivirus) 15 [34-42]
EEEV (togavirus) 1 [44]
CHIKV (togavirus) 1 [45]
other viruses
influenza A virus 2 [46,47]
herpes simplex virus 1 [48]
enterovirus 23 [49,50]
mumps virus 1 [53]
The outcome of IVIG-treatment was mostly favourable in the encephalitis
cases. However, three of 15 WNV encephalitis patients died from their disease
[34,38]. IVIG treatment had no influence on platelet recovery in 15 cases of
secondary DENV haemorrhagic infection, but caused no adverse events either.onset, i.e. from day 20 to 24 of his illness, the patient re-
ceived IVIG at a dose of 0.4 grams per kilogram body
weight each day. While the dysautonomic symptoms im-
proved and cardiac arrhythmia disappeared, the other
neurologic symptoms did not change, and a post-enceph-
alitic syndrome persisted that forced the patient into early
retirement [26]. In this context, it may be interesting to
note that actual IVIG preparations contain different levels
of anti-TBE antibodies, depending on their geographical
origin [27].
Japanese encephalitis virus
JEV is the most common cause of mosquito-borne flaviviral
encephalitis in Asia. About 30,000 to 50,000 cases are
reported annually. Contrary to TBE, mortality rate is high
in the range of 25 to 30%. Sequelae are observed in about
50% of those who survive [28,29]. A 49-year-old Italian
traveller to Vietnam with a severe form of JE showed exten-
sive T2-weighted hyper intensities in a MRI scan. T2-
weighted hyper intensities have also been described in other
JE cases [25,30]. A diagnosis was established by detecting
JEV-specific antibodies in the CSF and serum. The patient
was treated symptomatically, but his condition worsened
when on the sixth day of his disease a five day course of
IVIG at a dose of 0.4 grams per kilogram body weight each
day was started. It was not reported whether the applied
IVIG preparation contained specific anti-JEV antibodies.
Beginning with the next day, his condition started to
improve. After three weeks he was discharged with slight
symptoms of speech, motor and mental activity remaining,
but with a normal MRI. Only a slight deficit in recent
memory was observed one month after his discharge
[28,29].
In addition to hypotension, respiratory failure and gen-
eral meningoencephalitic symptoms, a 64-year-old man
with JE had prominent signs of Parkinsonism. MRI scans
showed T2-weighted hyper intensities in the thalamus
and substantia nigra that correspond to signs of Parkin-
sonism. A more than four-fold increase of specific anti-
bodies against JEV proved to be the cause of his disease.
A total of 40 grams of IVIG containing anti-JEV anti-
bodies was administered in two courses separated by
one month. His symptoms ameliorated after each course.
Although there were residual symptoms on discharge to
rehabilitation, the treatment was thought to have saved
the patient’s life [30].
Dengue virus
There are four subtypes of DENV and they are known
for more severe disease courses upon secondary infec-
tion. In such cases, a frequently observed symptom is a
pronounced thrombocytopenia leading to haemorrhage,
most likely due to bone marrow infection and, in
addition, possibly due to the clearance of thrombocytes
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worldwide annually due to dengue haemorrhagic fever
and is associated with an increased level of platelet-
associated IgG [31]. A randomized controlled study with
31 cases of secondary DENV infection in the Philippines
compared the effect of early intervention with high dose
IVIG versus non-intervention on platelet recovery. Begin-
ning with the second day of their hospitalization, IVIG was
given to 15 patients at a dose of 0.4 grams per kilogram
body weight each day for a three-day course. It was not
reported whether the IVIG-preparation (Gammamune,
Bayer Health Care, Brea, California) contained anti-DENV
antibodies. There was no effect on platelet recovery. The
authors concluded that platelet clearance by macrophages
through Fcγ-receptors is not the primary mechanism caus-
ing thrombocytopenia in this disease. However, an adverse
outcome associated with the IVIG treatment was not ob-
served in any of the IVIG-treated cases [31]. This indicates
that the administered IVIG did not cause ADE, although
enhancement has been shown to occur after secondary
DENV infection, mainly with another subtype [2,31]. Den-
gue infection may also cause a variety of neurological com-
plications which may result in poor recovery and long-term
disability. It remains to be studied whether the rare case of
DENV encephalitis or encephalopathy will respond to high
dose IVIG. The conduction of randomized clinical trials
investigating the potentially beneficial effects of IVIG for
the various life-threatening manifestations of dengue fever
has been proposed [32].
West Nile virus
WNV is originally endemic in East-Africa and the Middle
East. Beginning with a couple of cases in New York City,
between the years 1999 and 2002 WNV has conquered
the USA through a bird-, horse-, mosquito- and human-
cycle. WNV disease, including neurological involvement,
has a high mortality in the range of 5 to 14% [33,34]. Eight
cases of WNV encephalitis were treated with high dose
IVIG at a dose of 0.4 grams per kilogram body weight
each day for a five-day course. The blood used for this
IVIG preparation (Omrix Biopharmaceuticals Ltd., Israel)
was donated by healthy anti-WNV seropositive Israelis
and, therefore, contained high levels of specific anti-WNV
antibodies. Disease courses were severe, and four patients
needed mechanical ventilation. Additionally, MRI scans
were not systematically done. Six of the eight patients im-
proved significantly upon the high dose IVIG treatment
and were discharged, while two patients died from their
disease. One of the patients who died had received a kid-
ney transplant and was immune suppressed. The earlier
the immunoglobulin treatment started, the faster was the
improvement of the neurological symptoms. The two pa-
tients who died received high dose IVIG later than the fifth
day of their disease. The authors concluded that the earlyadministration of anti-WNV hyper immune high dose
IVIG should be recommended for WNV encephalitis [34].
Acute flaccid paralysis is a life-threatening complication
of WNV infection. A 55-year-old man with a quickly de-
veloping muscle weakness, reaching his respiratory mus-
cles on the third day so that the patient needed mechanical
ventilation was suspected to have a Guillain-Barré syn-
drome. Dexamethasone and plasmapheresis were ad-
ministered. When on the sixth day WNV was suspected,
corticosteroids and plasmapheresis were discontinued, and
anti-WNV hyper immune high dose IVIG at 0.4 grams per
kilogram body weight each day for a seven day course was
started instead. This treatment led to the rapid improve-
ment of his muscle weakness, so that the patient could be
discharged to inpatient rehabilitation after one month [35].
Since the WNV diagnosis was established on the basis of
an anti-WNV IgM in the serum, but IgG was not reported,
it cannot be formally excluded that the IgM might have
been a non-specific reactivity, since the acute flaccid par-
alysis might actually have had a different cause than WNV,
although the diagnosis seems most likely correct.
There are additional cases of WNV encephalitis mostly
successfully treated with anti-WNV hyper immune high
dose IVIG [36-42], among them are several solid organ
transplant patients [37,39-42]. A remarkable WNV case
report including a review of the literature was presented
by Rhee et al. (2011). The case report is unusual, because
the infection was transmitted through a transplanted liver.
When WNV was suspected in this case, serum was taken
for analysis and the patient received 0.4 grams of anti-
WNV hyper immune IVIG per kg body weight on the
fourth and eighth day of his hospitalization and recovered
fully. On the fifth day, a positive IgM, both in serum and
CSF samples, were obtained before the start of IVIG, and
the MRI scans pointed to WNV. Final proof came through
a positive WNV-PCR from a retained blood sample of the
liver donor who had not shown any WNV-typical symp-
toms at the time of his death through intracranial haemor-
rhage during a hypertensive crisis [41].
WNV with the highest number of case reports of
arboviral encephalitis treated with high dose IVIG is spe-
cial, because anti-WNV hyper immune IVIG preparations
are available. This means that, besides the immunomodula-
tory effects of generic high dose IVIG which is dampening
hyper inflammatory states without a noteworthy accom-
panying immune suppression, there is also a specific pro-
tective anti-WNV effect exerted by those immunoglobulin
preparations in animal experiments [43].
Eastern Equine encephalitis virus
EEE is caused by EEE virus belonging to the Togaviridae
family of the Alpha virus genus. EEE produces a mortal-
ity rate of about 30% and is the most severe of the
mosquito-borne encephalitides. Poor outcome has been
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severe hyponatremia, and a CSF white blood cell count
above 500 at symptom onset [44]. A 69-year-old man
with rapidly progressing EEE showed extensive T2-
hyperintensities in repeated MRI scans and became co-
matose on the third day of his illness. On the third day
of his hospitalization, one gram of methylprednisolon
per day was started and slowly tapered. The diagnosis
was established by identifying EEEV-specific antibodies
in the CSF and serum. On the fifth day, the patient was
given a total of 210 grams of generic IVIG over five days.
It was not reported whether the applied IVIG prepar-
ation contained anti-EEEV antibodies. Beginning with
the sixth hospital day, his condition started to improve.
After more than two months, he was discharged home
with few and relatively mild remaining symptoms, such
as mild inattention, bradykinesia, short-term memory
impairment, and emotional lability. All symptoms faded
during the following year [44].
Chikungunya virus
CHIKV is a mosquito-borne virus belonging to the
Togaviridae family of the Alpha virus genus. CHIKV typ-
ically causes a febrile disease in Africa and South-East Asia
that is characterized by severe joint pain and can become
haemorrhagic causing encephalitic symptoms in rare
cases. The virus has been imported to Europe through
international travel, and outbreaks have already occurred
in Europe, e.g. in Northern Italy. Three cases reporting
neurological symptoms were described by Chusri et al.
(2011). The cases showed hyper intense signals in the MRI
scan. Patient 1 was a 27-year-old woman who recovered
on supportive measures. Patient 2 was an 85-year-old man
who had not recovered during a follow-up one year later.
Patient 3, a 44-year-old woman, who suffered a very severe
form of late onset CHIKV encephalitis, was given a four
day course of high dose IVIG and quickly recovered upon
administration of the immunoglobulins and had recovered
completely at a follow-up after six months. It was not
reported whether the IVIG preparation contained anti-
CHIKV antibodies [45].
Other viruses
High dose IVIG has also been reported to play an advan-
tageous role in treating encephalitis induced by other
viruses. Two severe cases of influenza A virus-induced
encephalitis responded favourably [46,47]. Furthermore,
a case of brainstem encephalitis induced by herpes sim-
plex virus type I in an adult was effectively treated with
a combination of high dose aciclovir, steroids and IVIG
[48]. Early treatment of high dose IVIG has also been
reported to lead to a negative viral load faster for 55
children with prior malignant disease who suffered
severe enteroviral complications, including five cases ofencephalitis. Thus, early intervention was recommended
in order to improve the clinical outcome [49]. Another
clinical trial with 18 confirmed cases of enteroviral en-
cephalitis reported favourable clinical results after early
intervention with one gram IVIG per kilogram body weight
[50]. Acute disseminated encephalomyelitis (ADEM) is an
autoimmune phenomenon that has a similar clinical
appearance as viral encephalitis and may be triggered by in-
fections or, in rare cases, by vaccinations. Essentially, the
diagnosis of ADEM is based upon a combination of clinical
and radiologic features and the exclusion of specific diseases
that resemble ADEM. MRI scans again show disseminated
T2-weighted hyper intensities [51,52]. There are three cases
reported by Nishikawa et al. (1999) on the successful treat-
ment of ADEM with high dose IVIG. Although in most
cases of ADEM the trigger remains obscure, a mumps virus
infection was found to be the cause for post-infectious
ADEM in the third one of the described cases [53].
Potential caveats
Adverse effects of high dose IVIG
The diverse case reports discussed above suggest that
early intervention with high dose IVIG may be a general
treatment option for viral and post-infectious encephalit-
ides. Although IVIG is generally well tolerated, it is not
free from side effects. Adverse effects are mostly mild
that include aseptic meningitis, headache, fever, nausea,
diarrhoea, blood pressure changes and tachycardia. More
severe adverse effects include renal failure, thrombo-
embolic events and anaphylactic reactions that are re-
lated to IgA deficiency. The prior exclusion of an IgA
deficiency and the slow administration of IVIG in a suf-
ficiently large liquid volume helps to minimize the ser-
ious side effects [24].
Antibody dependent enhancement (ADE)
With the exception of secondary DENV infection, ADE
of flavivirus infection does not have any clear systematic
in vivo proof and is still under debate. Although en-
hancement was seen in cultured macrophages or mono-
cytes in vitro [9], it was not observed in TBE-infected
mice [10]. Passive post-exposure prophylaxis for non-
vaccinated persons was discontinued as a cautionary
measure and never re-introduced again due to a couple
of severe childhood TBE cases observed after adminis-
tering specific hyper immune serum to non-vaccinated
children after tick bites [6-8]. ADE of DENV infection of
Fcγ-receptor bearing cells has been ascribed to cross-
reactive non-neutralizing antibodies or to neutralizing
antibodies at sub-neutralizing levels [2]. This may be
due to the intermediate genetic distance of 60 to 75% at
the amino acid level between the four DENV subtypes.
Except for the tick-borne flaviviruses Powassan and TBE
virus that have an intermediate genetic distance of about
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quito-borne flaviviruses is below 50% [1]. Thus, cross-
enhancement should not occur between mosquito-borne
flaviviruses and the TBEV. Even if ADE might be operative
in TBE under rare circumstances, e.g. after prior infection
with WNV [54] or after vaccination against YF, both of
which is unlikely, or during infection at sub-protective
levels of anti-TBE antibodies, which anecdotally may have
been observed [6-8], these enhancing effects will most likely
be overridden by the anti-inflammatory action of high dose
generic IVIG. As a case in point, transiently immune
suppressed mice were not harmed by the administration of
specific anti-TBE antibodies. To the contrary, under transi-
ent immune suppression, serotherapy became more effi-
cient and mostly prevented persisting infections [55].
Summary
Active anti-TBEV vaccination continues to be the main-
stay of TBE prophylaxis [2]. Even with an overall high vac-
cination rate, however, some TBE cases experiencing a
severe disease course will remain. To our knowledge, early
intervention with high dose IVIG has not been reported
for TBE. A single severe TBE-case that we could find in
the literature improved upon application of high dose
IVIG late in the disease course [26]. Therefore, we wonder
whether early intervention with high dose IVIG may pose
a potentially successful treatment for TBE. However, also
late intervention may be promising.
If this is the case, it may be important to obtain immu-
noglobulins from blood donors vaccinated against TBE
[27], in analogy to anti-WNV hyper immune IVIG. Fur-
thermore, clinical symptoms, CSF laboratory parameters
including neopterin, together with a characteristic acute
phase MRI may allow an early tentative diagnosis, even
before serological test results are returned, and may in-
dicate an early intervention with high dose IVIG. We
propose to conduct a randomized controlled treatment
study on severe TBE cases.
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